Preclinical Data News Today

Poster Includes Preclinical Data on Novel Direct Pan-RAS Inhibitors CARLSBAD, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN) today announces a poster presentation on its preclinical Novel Direct Pan-RAS Inhibitors was presented at the American Association for Cancer Research (AACR) Annual Meeting 2024 held April 5 – 10 in San Diego, California. “We continue to see cancers developing resi...

Misetionamide showed broad antineoplastic activity in 15 different cancer types including multiple human cancer cell lines with no detrimental effect on...

—Proteomic Analysis of Human Samples Highlights the Unique Role of CCL24 in Activating Key PSC-related Disease Mechanisms Involving Immune Cell Trafficking and HSC Activation, Further Confirming the Potential of Chemomabs

Platform demonstrates robust in vivo editing capabilities reporting up to 70% editing of ACTB in the liver of non-human primates (NHPs) and miceFunctional effect demonstrated in mice in vivo via modulation of ANGPLT3 protein properties leading to favorable increase in LPL enzymatic activity and meaningful impact of biomarkersAdditional data to be presented throughout 2024, including in vitro and in vivo data for pipeline programs AX-0810 for Cholestatic diseases targeting NTCP and AX-1412 for Ca

Accusations against USC's Berislav Zlokovic were made by a small group of independent researchers and reported in the journal Science.

Misetionamide is effective in targeting and killing BRAF-mutated melanoma cells while preserving normal cellsBRAF-mutated melanoma accounts for...

Reported positive preliminary Phase 2 data on additional patients for HB-200 in combination with pembrolizumab in the 1st-line setting for advanced HPV16+ head and neck cancer; data reinforce strong objective response rate and disease control rate reported in Q2 2023; randomized trial expected to start in 2024 Published peer-reviewed preclinical data, in collaboration with Gilead Sciences, for HB-400 program in The Journal of Infectious Disease Recruitment ongoing for two Phase 1 clinical trials

Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today that it will present preclinical data of its lead asset, ACTM-838, in a poster presentation at the 2023 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting in San Diego, California. The presentation will feature data examining the tumor-specific enrichment and payload delivery of ACTM-838 in multiple tumor models.

SAN DIEGO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking plac...

VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinical indications PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutic...